

Specification

Application	WB
Primary Accession	Q99489
Other Accession	NM_003649 , NP_003640
Reactivity	Human, Rabbit, Pig, Horse, Bovine, Dog
Predicted	Human, Rabbit, Pig, Chicken, Horse, Bovine, Dog
Host	Rabbit
Clonality	Polyclonal
Calculated MW	41kDa KDa

Alias Symbol	DASOX, DDO-1, DDO-2, FLJ45203
Other Names	
D-aspartate oxidase, DASOX, DDO, 1.4.3.1, DDO	

Liquid. Purified antibody supplied in 1x PBS buffer with 0.09% (w/v) sodium azide and 2% sucrose.

Add 50 ul of distilled water. Final anti-DDO antibody concentration is 1 mg/ml in PBS buffer with 2% sucrose. For longer periods of storage, store at 20°C. Avoid repeat freeze-thaw cycles.

DDO antibody - N-terminal region is for research use only and not for use in diagnostic or therapeutic procedures.

Selectively catalyzes the oxidative deamination of acidic amino acids (PubMed:1991137, PubMed:20603179, PubMed:23391306, PubMed:25747990, PubMed:28393897, PubMed:28560262, PubMed:28629864, PubMed:<a

[29292239](http://www.uniprot.org/citations/29292239), PubMed: [31914658](http://www.uniprot.org/citations/31914658), PubMed: [32553892](http://www.uniprot.org/citations/32553892), PubMed: [9163533](http://www.uniprot.org/citations/9163533)). Suppresses the level of D-aspartate in the brain, an amino acid that can act as an agonist for glutamate receptors (PubMed: [28560262](http://www.uniprot.org/citations/28560262)). Protects the organism from the toxicity of D-amino acids (By similarity). May also function in the intestine (By similarity).

Cellular Location

Peroxisome matrix. Cytoplasm, cytosol. Note=Active in the peroxisomal matrix [Isoform 3]: Peroxisome matrix

Tissue Location


Expressed in epithelial cells of the proximal nephron tubules in the renal cortex (at protein level) (PubMed:12209855, PubMed:1991137). In the brain, expressed in the frontal, temporal, and occipital lobes of the cortex, hippocampus, striatum, diencephalon, brainstem, cerebellum, spinal cord, plexus choroideris and ependyma (at protein level) (PubMed:12209855, PubMed:28560262). Expression is increased in the prefrontal cortex of schizophrenic patients (PubMed:25689573). Levels are normal in the superior frontal gyrus of patients with Alzheimer's disease (PubMed:30822420).

DDO antibody - N-terminal region - Protocols

Provided below are standard protocols that you may find useful for product applications.

- [Western Blot](#)
- [Blocking Peptides](#)
- [Dot Blot](#)
- [Immunohistochemistry](#)
- [Immunofluorescence](#)
- [Immunoprecipitation](#)
- [Flow Cytometry](#)
- [Cell Culture](#)

DDO antibody - N-terminal region - Images



WB Suggested Anti-DDO Antibody Titration: 1.0 µg/ml
Positive Control: HepG2 Whole Cell

DDO antibody - N-terminal region - References

Setoyama C., et al. J. Biochem. 121:798-803(1997).

Ota T.,et al.Nat. Genet. 36:40-45(2004).

Mungall A.J.,et al.Nature 425:805-811(2003).

Mural R.J.,et al.Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.

Birkett C.,et al.Submitted (MAY-2005) to the EMBL/GenBank/DDBJ databases.